Overview
GAIA and Daiichi Sankyo Europe have entered an exclusive strategic partnership to commercialize lipodia, a digital therapeutic designed to support adults living with hypercholesterolemia, subject to regulatory approval.
The collaboration combines GAIA’s digital therapeutics expertise with Daiichi Sankyo’s cardiovascular healthcare capabilities to support long-term behaviour change alongside conventional treatment.
The News
Under the agreement, Daiichi Sankyo Europe will hold exclusive rights to lipodia, initially covering Germany, with mechanisms to expand into other major European markets. The fully automated digital therapeutic uses evidence-based behavioural health science and psychological and psychotherapeutic methods to adapt to individual patient needs through interactive dialogues and tools that support healthier routines.
The partnership aims to address behavioural risk factors associated with cardiovascular disease, including high cholesterol, poor diet, physical inactivity, obesity and stress. Lipodia is designed to be accessible on almost any connected device, enabling flexible, location-independent use.
GAIA plans to submit lipodia for reimbursement once data from its pivotal Phase 3 randomised controlled trial become available. Following regulatory approval, the therapy could be prescribed by physicians and reimbursed through Germany’s statutory health insurance DiGA pathway.
Industry Perspective
Cardiovascular disease remains Europe’s leading cause of death, while many cardiovascular events are linked to modifiable risk factors. Digital therapeutics are increasingly being explored as a way to complement medicines with structured behavioural support and improve long-term patient engagement.
Strategic Impact
The partnership expands Daiichi Sankyo Europe’s cardiovascular portfolio into digital therapeutics and could position lipodia as a scalable complement to established hypercholesterolemia care. By combining pharmacological treatment with personalised behavioural support and a potential reimbursement pathway, the collaboration aims to improve access to integrated cardiovascular care across Germany and, potentially, other European markets.
Source: Businesswire
